BioAge Labs to present at the Piper Sandler Healthcare Conference, showcasing advances in metabolic disease therapeutics.
Quiver AI Summary
BioAge Labs, Inc., a clinical-stage biotechnology company focused on developing therapies for metabolic diseases by targeting human aging, announced its participation in the Piper Sandler 37th Annual Healthcare Conference in New York from December 2-4, 2025. CEO Kristen Fortney and CFO Dov Goldstein will engage in a fireside chat on December 4 and meet with investors individually. BioAge's lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor being tested for obesity and cardiovascular risks, with initial clinical trial data expected soon. The company is also working on additional treatments for obesity based on its proprietary research into human longevity. Webcast access and future replays are available on the company's website.
Potential Positives
- BioAge Labs is actively participating in a major healthcare conference, which could enhance its visibility and credibility in the biotechnology industry.
- The company is showcasing its lead product candidate, BGE-102, which targets metabolic diseases, indicating ongoing progress in its clinical trials.
- Initial safety and pharmacodynamics data of BGE-102 is anticipated soon, potentially providing valuable insights and momentum for the company's development plans.
- The presentation by the CEO and CFO suggests strong leadership engagement, which may positively influence investor confidence and stakeholder interest.
Potential Negatives
- The press release does not provide specific details or results regarding the ongoing Phase 1 trial of BGE-102, which could raise concerns about the transparency and progress of their lead product candidate.
- While the announcement of participation in a major healthcare conference is positive, it may also indicate a need for increased visibility and credibility in a competitive biotechnology sector.
FAQ
What is BioAge Labs, Inc. known for?
BioAge Labs, Inc. focuses on developing therapeutic candidates for metabolic diseases by targeting human aging biology.
When will BioAge present at the Piper Sandler Conference?
BioAge will present at the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025.
Who from BioAge will speak at the conference?
CEO Kristen Fortney, PhD, and CFO Dov Goldstein, MD, will represent BioAge in a fireside chat.
How can I access the presentation webcast?
You can access the live webcast by registering through the link provided in the press release.
What is BioAge's lead product candidate?
BioAge's lead product candidate is BGE-102, a small-molecule NLRP3 inhibitor for obesity and cardiovascular risks.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BIOA Hedge Fund Activity
We have seen 39 institutional investors add shares of $BIOA stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SUVRETTA CAPITAL MANAGEMENT, LLC removed 1,452,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $5,998,147
- RA CAPITAL MANAGEMENT, L.P. removed 1,052,494 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,346,800
- RTW INVESTMENTS, LP removed 786,353 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,247,637
- MILLENNIUM MANAGEMENT LLC added 270,479 shares (+749.8%) to their portfolio in Q3 2025, for an estimated $1,590,416
- CANTOR FITZGERALD, L. P. removed 200,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,176,000
- ORBIMED ADVISORS LLC removed 131,058 shares (-14.2%) from their portfolio in Q3 2025, for an estimated $770,621
- HOWARD HUGHES MEDICAL INSTITUTE removed 113,765 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $469,849
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BIOA Analyst Ratings
Wall Street analysts have issued reports on $BIOA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 10/29/2025
To track analyst ratings and price targets for $BIOA, check out Quiver Quantitative's $BIOA forecast page.
Full Release
EMERYVILLE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference taking place in New York, NY on December 2-4, 2025.
Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Thursday, December 4 from 1:30 - 1:55 PM ET, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here .
Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/ , and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity and cardiovascular risk factors. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, [email protected]
IR: Dov Goldstein, [email protected]
Partnering: [email protected]
Web: https://bioagelabs.com
